1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Three Is The Magic Number: Celltrion Lines Up A Trio Of European Biosimilars

As Biocon Biologics And Aurobindo’s CuraTeQ Also Pick Up EMA Nods

 
• By Dave Wallace

Celltrion has emerged from the latest CHMP meeting at the EMA with three new biosimilars lined up for approval. At the same time, Biocon Biologics and Aurobindo’s CuraTeQ have also picked up positive opinions for biosimilars, while Neuraxpharm has won endorsements for a pair of hybrids.

Celltrion has received EU nods for three biosimilars (Shutterstock)

Celltrion is celebrating after lining up a trio of biosimilars for approval in the EU. The European Medicines Agency’s Committee for Medicinal Products for Human Use issued positive opinions for four Celltrion products across three molecules at its December meeting, recommending that the European Commission grant marketing authorizations for the Korean firm’s aflibercept, denosumab and tocilizumab biosimilars.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Celltrion Celebrates Interchangeability Designation For Humira Biosimilar In The US

 
• By Urtė Fultinavičiūtė

Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

More from Generics Bulletin

Sunshine Becomes Latest To Compete On Everolimus In Canada

 
• By Dave Wallace

Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Trihexyphenidyl Tablets Treble In A Busy March For UK Price Rises

 
• By Dave Wallace

Trihexyphenidyl tablets in two different strengths led a raft of UK generic price rises in March, according to the latest figures from WaveData.